A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer

Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm

NCT05546866 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer

NCT04426825 ·Status: COMPLETED ·Phase: PHASE2

A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation

NCT04951648 ·Status: UNKNOWN ·Phase: PHASE3

Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Treatment in NSCLC With EGFR M(-) and C-met(-)

NCT02006043 ·Status: UNKNOWN ·Phase: PHASE2

A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC

NCT04580498 ·Status: UNKNOWN ·Phase: PHASE2

Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC

NCT04768491 ·Status: UNKNOWN

Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer

NCT05435274 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation

NCT05548348 ·Status: RECRUITING ·Phase: PHASE2

Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC

NCT05536505 ·Status: RECRUITING ·Phase: PHASE2

A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer

NCT05047250 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Epidermal Growth Factor Receptor and K-ras Mutations in Patients With Stage III Non-Small Cell Lung Cancer

NCT00898924 ·Status: COMPLETED

Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma

NCT06383728 ·Status: RECRUITING ·Phase: PHASE2

Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations

NCT04687241 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

NCT05104788 ·Status: RECRUITING ·Phase: PHASE2

Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer

NCT04685070 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer

NCT05284539 ·Status: RECRUITING ·Phase: PHASE2

Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)

NCT05435248 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Almonertinib for Advanced NSCLC Patients With Rare Mutations in EGFR

NCT04785742 ·Status: UNKNOWN ·Phase: PHASE2

Nimotuzumab Plus Docetaxel in Chemotherapy-Refractory/Resistant Patients With Advanced Non-Small-Cell Lung Cancer

NCT00983047 ·Status: TERMINATED ·Phase: PHASE2

Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.

NCT06452433 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma

NCT05165355 ·Status: UNKNOWN ·Phase: PHASE2

Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer

NCT03749213 ·Status: UNKNOWN ·Phase: PHASE2

Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases

NCT07343479 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery

NCT02804776 ·Status: COMPLETED ·Phase: PHASE2

First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation

NCT02883543 ·Status: UNKNOWN ·Phase: PHASE3